Globally,
Glaucoma is on rise. According to the Glaucoma research Foundation,
Glaucoma is the leading cause of irreversible blindness globally.
Nearly 10% of the glaucoma patients who receive proper treatment
still experience a loss of vision. Around 64.3 million people were
estimated to be having glaucoma globally in 2013. Furthermore,
according to the American Academy of Ophthalmology, the current
prevalence is high in Africa, and Latin America. Patients who fail to
respond to medications, undergo trabeculectomy surgery. However, few
patients do not get completely relieved from glaucoma even after
trabeculectomy surgery. Therefore, novel treatment options are
required to be introduced for providing relief to such patients.
Reducing intra-ocular pressure is the most important long term
medical need of refractory glaucoma patients.
Get
Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/71
Future
Market Dynamics
According
to the American Academy of Ophthalmology, the global prevalence of
glaucoma is estimated to rise to 76 million in 2020 and 111.8 million
in 2040. Rapidly aging population will be one of the important
factors for the increasing prevalence rate. There would be a
disproportionate rise in the prevalence in people residing in Asia
and Africa. Slower adoption rate and high cost of the surgery is
limiting the market growth of refractory glaucoma treatment devices
in emerging nations where cataract surgery is the largely performed
eye surgery. With new devices and technology being introduced, there
could be a strong wave of growth experienced in the North America and
European markets.
Refractory
Glaucoma Treatment Options
The
global refractory glaucoma treatment market can be characterized
based on the treatment options and devices available in the market.
Ahmed
Glaucoma Valve from New World Medical Inc., is a good treatment
option available since 1993 for refractory glaucoma. This device also
has applications in primary open angle glaucoma unresponsive to
medication, neovascular glaucoma, and congenital or infantile
glaucoma. Various studies have reflected the positive outcomes of
using Ahmed Glaucoma Valve in refractory glaucoma both in pediatrics
and adults. Therefore, this device is in very high demand and usage
globally.
Alternate
option like CyPass Micro-Stent from Transcend Medical showed
impressive results in patients with primary open-angle glaucoma.
CyPass is a micro-invasive surgery which according to the FDA
guidelines needs to be performed in combination with cataract
surgery. This is restricting the wider acceptance among patients due
to increased cost.
Clinical
trials of Xen System showed positive results with 44% reduction in
eye pressure and 65% reduction in IOP medications in one year period.
The Xen gel stent form Allergan reduces IOP with a permanent implant
that becomes flexible, allowing doctors to use IOP reduction
therapies event after the Xen implantation. Allergan received U.S.
FDA approval for Xen Gel stent in November 2016. The company plans to
launch the Xen Gel stent in the U.S. market, for refractory glaucoma
treatment, in early 2017. The Xen system has already received CE mark
and has distributed more than 10,500 stents globally. Moreover, the
new surgical system is also licensed for use in Canada, Switzerland,
and Turkey.
Iridex
Corporation, a global provider of innovative laser systems, device
and consumables in ophthalmology announced at the European Glaucoma
Society held in June 2016 about the positive results of its
MicroPulse P3 (MP3) device. The device powered with MicroPulse laser
technology showed long term benefits for patients with refractory
glaucoma. Few detailed studies with successful outcomes could lead
global acceptance of this technology in future.
For
More Information, Browse Full Report Here:
https://www.coherentmarketinsights.com/ongoing-insight/refractory-glaucoma-treatment-market-71
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment